Gilead Sciences Inc. (GILD)

72.44
0.48 0.66
NASDAQ : Health Technology
Prev Close 72.92
Open 72.94
Day Low/High 72.64 / 73.37
52 Wk Low/High 64.27 / 89.54
Volume 1.36M
Avg Volume 6.48M
Exchange NASDAQ
Shares Outstanding 1.30B
Market Cap 97.99B
EPS 3.50
P/E Ratio 44.20
Div & Yield 2.28 (2.91%)

Latest News

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide), A Single Tablet Regimen For The Treatment Of HIV-1 Infection

China National Drug Administration Approves Gilead's Genvoya® (Elvitegravir, Cobicistat, Emtricitabine And Tenofovir Alafenamide), A Single Tablet Regimen For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that the China National Drug Administration (CNDA) has approved Genvoya ® (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1...

Why Investors Should Favor Smaller Biotech Companies

Why Investors Should Favor Smaller Biotech Companies

Small and mid-cap biotech firms are driving innovation in the sector. Experts explain why investors should take notice.

Gilead's Earnings Fail to Impress

Gilead's Earnings Fail to Impress

The company is losing sales aggressively as it fails to create any business substantial enough to make up for the shrinking sales in its Hepatitis C drugs.

Gilead Sciences Announces Third Quarter 2018 Dividend

Gilead Sciences Announces Third Quarter 2018 Dividend

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the company's Board of Directors has declared a cash dividend of $0.

Gilead Sciences Announces Second Quarter 2018 Financial Results

Gilead Sciences Announces Second Quarter 2018 Financial Results

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the second quarter ended June 30, 2018.

Gilead Sciences Announces CEO John F. Milligan To Step Down

Gilead Sciences Announces CEO John F. Milligan To Step Down

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that John F.

Buy These 3 Risky Biotech Stocks

Buy These 3 Risky Biotech Stocks

Is the pharma sector fever heating up in 2H18? Drug investors, get ready as there could be some good trades to be made.

Gilead Announces New Data On The Impact Of Truvada® (Emtricitabine And Tenofovir Disoproxil Fumarate) For Pre-Exposure Prophylaxis (PrEP) On The Number Of HIV Diagnoses In The United States

Gilead Announces New Data On The Impact Of Truvada® (Emtricitabine And Tenofovir Disoproxil Fumarate) For Pre-Exposure Prophylaxis (PrEP) On The Number Of HIV Diagnoses In The United States

Gilead Sciences, Inc. (NASDAQ: GILD) today announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg tablets) for pre-exposure prophylaxis (PrEP) use across all 50 U.

Kite And Gadeta Announce Strategic Collaboration To Advance Gamma Delta T Cell Receptor Technology For Solid Tumors

Kite And Gadeta Announce Strategic Collaboration To Advance Gamma Delta T Cell Receptor Technology For Solid Tumors

Kite, a Gilead Company (Nasdaq: GILD), and Gadeta B.V.

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Biotech's Coming Back to Life: Cramer's 'Off the Charts'

Some beaten up biotech names are finally coming back to life. Here's a look at the technical analysis.

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Market Refuses To Go Lower: Cramer's 'Mad Money' Recap (Tuesday 7/17/18)

Investors have never gone wrong buying Netflix on the dips. Jim Cramer tells you what to make of the 'FANG Musketeers.'

Gilead Sciences To Release Second Quarter 2018 Financial Results On Wednesday, July 25, 2018

Gilead Sciences To Release Second Quarter 2018 Financial Results On Wednesday, July 25, 2018

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes.

Michael Amoroso To Join Kite As Senior Vice President And Head Of Worldwide Commercial, Cell Therapy

Michael Amoroso To Join Kite As Senior Vice President And Head Of Worldwide Commercial, Cell Therapy

Kite, a Gilead Company (NASDAQ: GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy.

Chart of the Day: Gilead Sciences

GILD is finally showing some robust price action.

Biotech Stocks Rally on Biogen's Landmark Test

Biotech Stocks Rally on Biogen's Landmark Test

Investors might be finally recognizing the hidden value of the firms' drug research and development.

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

Gilead Sciences Is Displaying a Bullish Long-Term Pattern

This biotech's weekly chart is very encouraging.

European CHMP Adopts Positive Opinion For Yescarta® (axicabtagene Ciloleucel) For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

European CHMP Adopts Positive Opinion For Yescarta® (axicabtagene Ciloleucel) For The Treatment Of Relapsed Or Refractory DLBCL And PMBCL, After Two Or More Lines Of Systemic Therapy

Kite, a Gilead Company (Nasdaq: GILD), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion on the company's Marketing Authorization Application (MAA) for Yescarta ®...

European Commission Grants Marketing Authorization For Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

European Commission Grants Marketing Authorization For Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) For The Treatment Of HIV-1 Infection

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the European Commission has granted Marketing Authorization for Biktarvy ® (bictegravir 50mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg; BIC/FTC/TAF), a once-daily single tablet regimen (STR)...

Snap, Gilead Sciences, Cronos Group: 'Mad Money' Lightning Round

Snap, Gilead Sciences, Cronos Group: 'Mad Money' Lightning Round

Jim Cramer takes a look at Snap, Gilead Sciences, Cronos Group, TrustCo Bank, CRISPR Therapeutics, Iron Mountian, Prudential and more.

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

The Trouble With Trump's Tariffs: Cramer's 'Mad Money' Recap (Friday 6/22/18)

Trump's doubling down on trade issues. If you can't stand the pressure, then raise cash. Jim Cramer has your game plan for next week.

Jim Cramer: Confounding Days

Jim Cramer: Confounding Days

The buyers of stocks on days like Tuesday make very little sense.

50 Stocks Goldman Sachs Thinks Can Triumph Over Wage Inflation

50 Stocks Goldman Sachs Thinks Can Triumph Over Wage Inflation

Looking for stocks that could outperform during the current period of labor inflation? Try building a portfolio of these 50 stocks.

12 Stocks That Make Up the GLUM Index

12 Stocks That Make Up the GLUM Index

Here is a new index for all you traders out there to follow, compliments of TheStreet's founder Jim Cramer. Welcome to the GLUM Index.

Jim Cramer: A GLUM Index For Gloomy Markets

Jim Cramer: A GLUM Index For Gloomy Markets

Taking the measure of what's keeping the markets in the dumps.

Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer Of The Order Of Australia

Gilead Sciences' Chief Scientific Officer John McHutchison Appointed Officer Of The Order Of Australia

Gilead Sciences, Inc. (NASDAQ: GILD) announced today that John McHutchison, MD, Chief Scientific Officer and Head of Research and Development, has been appointed an Officer of the Order of Australia in recognition of his "distinguished service to medical...

Gilead Sciences Announces Leadership Changes In Corporate Development And Strategy

Gilead Sciences Announces Leadership Changes In Corporate Development And Strategy

Gilead Sciences, Inc. (NASDAQ: GILD) today announced the promotion of Andrew Dickinson to Executive Vice President, Corporate Development and Strategy, with responsibility for Gilead's corporate development, alliance management, competitive intelligence,...

Jim Cramer: Move Over FANG, Long Live INJFANG

Jim Cramer: Move Over FANG, Long Live INJFANG

The Nasdaq hit an all-time high today, and It's Not Just FANG anymore.

Kite Announces New Data Analyses For CAR T Therapy In Patients With Blood Cancers At The 2018 American Society Of Clinical Oncology Meeting

Kite Announces New Data Analyses For CAR T Therapy In Patients With Blood Cancers At The 2018 American Society Of Clinical Oncology Meeting

Kite, a Gilead Company (Nasdaq: GILD), today announced new analyses from the ZUMA chimeric antigen receptor T (CAR T) cell therapy development program that are being presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in...

TheStreet Quant Rating: C (Hold)